Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muzastotug + INCA33890
- Development stage
- Phase 1
- Lead developer
- Adagene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
muzastotug + INCA33890 is an investigational combination immunotherapy consisting of muzastotug (ADG126), a masked anti-CTLA-4 monoclonal antibody (SAFEbody) developed by Adagene, and INCA33890, a bispecific antibody targeting TGFβR2 and PD-1 developed by Incyte (in collaboration with Merus). Muzastotug is designed to selectively deplete regulatory T cells (Tregs) in the tumor microenvironment by targeting a specific CTLA-4 epitope, while minimizing systemic toxicity through its masking technology. INCA33890 simultaneously blocks the PD-1 and TGF-β pathways, which are key drivers of immune evasion and T-cell suppression. The combination is being evaluated in a Phase 1 clinical trial sponsored by Incyte for the treatment of patients with third-line microsatellite-stable colorectal cancer (MSS CRC), with or without liver metastases.
- Other names
- ADG126 + INCA33890ADG126 and INCA33890ADG-126 and INCA33890ADG 126 and INCA33890muzastotug and INCA33890
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on muzastotug + INCA33890.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muzastotug + INCA33890.